On the morning of the 29th, Solux's stock price is rising over 20%. This comes as news breaks that Aribio, which is pursuing a merger with Solux, has finalized an official contract with a Chinese pharmaceutical company.
As of 9:24 a.m. on the 29th, Solux is trading at 6,150 won, up 1,200 won (24.24%) compared to the previous trading day in the KOSDAQ market.
The news that uncertainties related to the contract with China, which had posed an obstacle to the merger with Solux, have been resolved seems to have attracted buying interest.
On this day, Aribio announced that it has selected the Chinese pharmaceutical company Puxing as a partner to handle the manufacturing and commercialization of its oral Alzheimer's treatment 'AR1001' in the Greater China region. This is a exclusive sales contract, and it is reported that preparations for the commercialization of AR1001 in the Greater China region have been completed.